Soft capsule capable of resisting oxidation and protecting nerve cells and preparation process of soft capsule

By combining glycerol choline phosphate, ergothioneine, algae oil DHA and PQQ, antioxidant protective nerve cell soft capsules are prepared, which solves the problem that the existing technology is difficult to effectively protect nerve cells, and achieves significant neuroprotection and anti-aging Oxidation effect, prolong life, prevent disease and anti-aging.

CN119015251APending Publication Date: 2024-11-26SHANGHAI HOO PHARM CO LTD

Patent Information

Application Number
CN202411172052.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The incidence of major brain diseases such as stroke, Alzheimer's disease, Parkinson's disease, etc. is rising due to nerve cell damage, and it is difficult for the existing technology to effectively protect nerve cells, prevent diseases and fight aging.

Method used

Antioxidant protective nerve cell soft capsules are prepared by using glycerol phosphocholine, ergothioneine, algae oil DHA and PQQ as main ingredients, combined with natural vitamin E, medium-chain triglycerides, non-transformed phospholipids and beeswax, and synergistic effects are used to exert Antioxidant and neuroprotective effects, and improves the stability and absorption of ingredients through specific preparation processes.

Benefits of technology

Significantly improve nerve conduction function, provide comprehensive neuroprotection, improve cognitive function, reduce oxidative stress and inflammatory response, prolong life, enhance the body's antioxidant ability, and effectively prevent diseases and anti-aging.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention relates to an antioxidant nerve cell protection soft capsule and a preparation process thereof, and belongs to the technical field of health care products. The glycerophosphorylcholine, the ergothioneine, the algal oil and the pyrroloquinoline quinone are used as main components to be effectively combined, a better anti-oxidation effect is achieved through the synergistic effect among the main components, and meanwhile, wider neuroprotection is provided by combining the effects among the substances; the natural vitamin E, the medium chain triglyceride, the non-transphospholipid and the beewax are added as auxiliary materials, so that the stability of the formula and the absorption of fat-soluble components are improved; the soft capsule prepared by the invention has excellent oxidation resistance and can protect nerve cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of health products and relates to an anti-oxidation soft capsule for protecting nerve cells and a preparation process thereof. Background Art

[0002] Under normal circumstances, the free radicals in the human body are in a dynamic balance of continuous generation and removal. If the free radicals are produced too much or removed too slowly, they will attack the macromolecules of life and various cells, causing various damages to the body at the molecular level, cellular level and tissue and organ level, accelerating the aging process of the body and inducing various diseases. While the human body inevitably produces free radicals, it also naturally produces antioxidant substances to resist free radicals to offset the oxidative attack of free radicals on human cells. Studies have shown that the human body's antioxidant system is a system with complete and complex functions comparable to the immune system. The stronger the body's antioxidant ability, the healthier it is and the longer its life. The body's antioxidant effect can maintain a balance between the generation and elimination of free radicals, which is of great significance for preventing diseases and anti-aging.

[0003] The incidence of major brain diseases such as stroke, Alzheimer's disease (AD), Parkinson's disease (PD), depression and schizophrenia has been rising, becoming a major problem that seriously endangers human health and has received great attention. With the improvement of people's living standards and the enhancement of health awareness, more and more people have begun to pay attention to neurological health issues. People hope to protect the nervous system through various means to avoid the occurrence of related diseases. These brain diseases are all common pathological processes in which nerve cells are damaged.

[0004] Therefore, a health product with neuroprotective effect is developed to achieve the related uses of anti-oxidation and nerve protection. Summary of the invention

[0005] The object of the present invention is to provide an antioxidant soft capsule for protecting nerve cells and a preparation process thereof. The present invention effectively combines glycerophosphocholine GPC, ergothioneine, algae oil DHA and PQQ as main components, exerts a better antioxidant effect through the synergistic effect between each other, and provides a wider range of nerve protection in combination with the effects between the substances, and adds natural vitamin E, medium-chain triglycerides, non-transformed phospholipids and beeswax as auxiliary materials to exert antioxidant properties to increase the stability of the formula, and then improves the absorption of fat-soluble components through medium-chain triglycerides, and can exert multiple functions of various substances at the same time, such as antioxidant properties, to protect nerve cells.

[0006] The purpose of the present invention can be achieved through the following technical solutions:

[0007] The invention discloses an anti-oxidation and nerve cell protection soft capsule, comprising a soft capsule shell and capsule contents, wherein each portion of the capsule contents comprises the following components in parts by weight: 200-205 portions of glycerylphosphorylcholine GPC, 250-260 portions of algae oil DHA, 25-27 portions of ergothioneine, 10-12 portions of pyrroloquinoline quinone PQQ, 5-6 portions of natural vitamin E, 73-75 portions of medium-chain triglyceride MCT, 30-33 portions of non-transgenic phospholipids and 20-22 portions of beeswax; the soft capsule shell is prepared by gelatin, purified water and glycerol.

[0008] A preparation process of an anti-oxidation and nerve cell protection soft capsule comprises the following steps:

[0009] S1. Preheat the mixture of gelatin, purified water and glycerin to 78-82°C under vacuum conditions, pour it into a suction bucket and suck it into a steam-sterilized concentrator through a pipeline;

[0010] S2. Continue to raise the temperature at a steam pressure of 0.06-0.1 MPa until the mixture is completely dissolved to obtain a mixed solution;

[0011] S3, continue heating to 100-105°C to perform vacuum degassing on the mixed solution;

[0012] S4, filtering the mixed solution at a pressure of 0.03-0.06 MPa and a temperature of 58-62° C. to obtain a capsule solution;

[0013] S5, pouring the capsule shell solution into a molding container of a capsule molding machine, drying and shrinking the soft capsule shell to reduce the moisture content of the soft capsule shell to 5-7%, and then washing with 95% ethanol to remove the oil stain on the surface of the soft capsule shell;

[0014] S6. At 24° C., mix glycerylphosphorylcholine GPC, algae oil DHA, ergothioneine, pyrroloquinoline quinone PQQ, natural vitamin E, medium-chain triglyceride MCT, non-transformed phospholipids and beeswax in proportions by weight.

[0015] S7, controlling the temperature at 18-26° C. and the relative humidity at 45-55%, filling the mixture obtained in step S6 into capsule shells through a soft capsule machine, and pressing into soft capsules;

[0016] S8, placing the soft capsule in an environment with a temperature of 18-26° C. and a relative humidity of 35% for 2-4 hours to obtain the anti-oxidation soft capsule for protecting nerve cells.

[0017] As a preferred technical solution of the present invention, in step S1, the mass ratio of gelatin, purified water and glycerol is 100:100:35.

[0018] As a preferred technical solution of the present invention, in step S1, the steam sterilization temperature is 100-110°C and the time is 15-20 minutes.

[0019] As a preferred technical solution of the present invention, in step S3, the vacuum degree during vacuum degassing is -0.08 to -0.1 MPa, and the temperature is 60°C.

[0020] As a preferred technical solution of the present invention, in step S5, the drying and shrinking conditions are a temperature of 25 to 30° C., a relative humidity of 35%, and a time of 18 to 24 hours.

[0021] GPC is phosphatidylcholine, which is the product of complete hydrolysis of the two fatty acyl groups on the lecithin molecule. It is a water-soluble phospholipid precursor and neurotransmitter naturally present in the human body. As a choline precursor, it can support the fluidity and integrity of cell membranes.

[0022] In the present invention, GPC and DHA have a synergistic effect. GPC can increase the level of acetylcholine and promote nerve conduction. As an important component of the brain cell membrane, DHA can ensure the efficiency of nerve signal transmission and the health of the cell membrane in the process of GPC promoting nerve conduction. The two work together to significantly improve the nerve conduction function. At the same time, both GPC and DHA have a neuroprotective effect. GPC reduces neuroinflammation, and DHA protects nerve cells by maintaining cell membrane health and anti-inflammatory effects.

[0023] In the present invention, GPC and PQQ also have a synergistic effect. GPC directly improves memory and learning functions by increasing acetylcholine levels, while PQQ indirectly supports cognitive functions by promoting mitochondrial generation and enhancing cellular energy metabolism. The synergistic effect of the two can jointly improve cognitive functions from different levels (neurotransmitters and energy metabolism); GPC and PQQ both have neuroprotective effects. GPC reduces neuroinflammation, and PQQ reduces oxidative stress, providing more comprehensive neuroprotection under synergistic effects.

[0024] In the present invention, GPC and ergothioneine have a synergistic effect. The powerful antioxidant effect of ergothioneine combined with the anti-inflammatory effect of GPC can effectively reduce oxidative stress and inflammatory response in the brain and protect nerve cells. The combination of the two can provide a wider range of neuroprotection. GPC protects nerve conduction by increasing acetylcholine levels, and ergothioneine reduces nerve cell damage by anti-oxidation.

[0025] At the same time, the synergistic effect of PQQ and DHA: PQQ promotes mitochondrial generation and function, providing sufficient energy support; DHA maintains cell membrane health and ensures the normal function of mitochondria. The synergistic effect of the two can improve the overall function and health of nerve cells; PQQ works through antioxidant and neuroprotective effects, and DHA works through strengthening brain cell membranes and anti-inflammatory effects. The two work together to significantly improve cognitive function and provide comprehensive neuroprotection.

[0026] Synergistic effect of ergothioneine and PQQ: Both ergothioneine and PQQ have powerful antioxidant effects. Ergothioneine scavenges free radicals and PQQ reduces oxidative stress. The combination of the two can significantly reduce oxidative damage in the brain and protect nerve cells. PQQ promotes mitochondrial generation and function, and ergothioneine protects mitochondria from oxidative damage. The two work synergistically to ensure the normal function of mitochondria and maintain the health of nerve cells.

[0027] Synergistic effect of ergothioneine and DHA: The antioxidant effect of ergothioneine and the anti-inflammatory effect of DHA combined can significantly reduce inflammation and oxidative stress in the brain and protect nerve cells; DHA maintains the health of brain cell membranes, and ergothioneine protects nerve cells through antioxidant effects. The two work synergistically to provide comprehensive neuroprotection.

[0028] In the present invention, the dosage form is made into a soft capsule, which can effectively isolate air and light, reduce the oxidation and decomposition of algae oil DHA, improve the bioavailability of active ingredients, especially improve the absorption of fat-soluble ingredients glycerophosphocholine and algae oil DHA, and cover the fishy smell of algae oil DHA; and the content of each dose of ingredients can be accurately controlled to ensure that a consistent amount of ingredients can be taken each time it is taken, reducing dosage errors. The soft capsule can flexibly and effectively combine glycerophosphocholine, ergothioneine, algae oil DHA and PQQ to ensure the stability and synergy of each ingredient.

[0029] Beneficial effects of the present invention:

[0030] In the present invention, glycerophosphocholine GPC, ergothioneine, algae oil DHA and PQQ are effectively combined as main components, and a better antioxidant effect is exerted through the synergistic effect between each other. At the same time, a wider range of nerve protection is provided by combining the effects of various substances, and natural vitamin E, medium-chain triglycerides, non-transgenic phospholipids and beeswax are added as auxiliary materials to increase the stability of the formula and the absorption of fat-soluble components, and at the same time, the multiple functions of various substances can be exerted, such as antioxidant property, to protect nerve cells. DETAILED DESCRIPTION

[0031] In order to further illustrate the technical means and effects adopted by the present invention to achieve the predetermined invention purpose, the specific implementation methods, structures, features and effects of the present invention are described in detail below in combination with the embodiments.

[0032] Raw materials used in the following examples and comparative examples:

[0033] Glycerylphosphorylcholine: purchased from Wuxi Maijie Biotechnology Co., Ltd.

[0034] Algal oil DHA: purchased from Shaanxi Haisifu Bioengineering Co., Ltd.;

[0035] Ergothioneine: purchased from Jiangsu Jinsan Biotechnology Co., Ltd.;

[0036] Pyrroloquinoline quinone PQQ: purchased from Shaanxi NewZhenyuan Biotechnology Co., Ltd.;

[0037] Natural vitamin E: purchased from Shaanxi Haisifu Bioengineering Co., Ltd.;

[0038] Medium chain triglycerides: purchased from Daoqin Biotechnology (Shanghai) Co., Ltd.;

[0039] Non-transgenic phospholipids: purchased from Anhui Yuanchuang Technology Co., Ltd.;

[0040] Beeswax: purchased from Cangzhou Fengzhiyi Wax Industry Co., Ltd.

[0041] Gelatin: purchased from Shandong Hengxin Biotechnology Co., Ltd.;

[0042] Glycerol: purchased from Wilmar Biotech (Shanghai) Co., Ltd.

[0043] Example 1

[0044] Each capsule content includes the following ingredients in parts by weight: 200 mg glycerylphosphorylcholine GPC, 260 mg algae oil DHA, 27 mg ergothioneine, 10 mg pyrroloquinoline quinone PQQ, 6 mg natural vitamin E, 73 mg medium chain triglyceride MCT, 33 mg non-transgenic phospholipids and 22 mg beeswax.

[0045] S1. Under vacuum conditions, preheat a mixture of gelatin, purified water and glycerin in a mass ratio of 100:100:35 to 78°C, pour it into a suction barrel and suck it into a steam-sterilized concentration pot through a pipeline, wherein the steam sterilization temperature is 100°C and the time is 15 minutes;

[0046] S2. Under a steam pressure of 0.06 MPa, continue to heat until the mixture is completely dissolved to obtain a mixed solution;

[0047] S3, continue heating to 100°C and perform vacuum degassing treatment on the mixed solution at a vacuum degree of -0.08MPa and a temperature of 60°C;

[0048] S4, filtering the mixed solution at a pressure of 0.03 MPa and a temperature of 58° C. to obtain a capsule solution;

[0049] S5, pouring the capsule shell solution into the molding container of the capsule molding machine, drying and shrinking for 18 hours at a temperature of 25° C. and a relative humidity of 35%, so that the moisture content of the soft capsule shell is reduced to 5%, and then washing with 95% ethanol to wash away the oil on the surface of the soft capsule shell;

[0050] S6. Under the condition of 24°C, glycerylphosphorylcholine GPC, algae oil DHA, ergothioneine, pyrroloquinoline quinone PQQ, natural vitamin E, medium chain triglyceride MCT, non-transgenic phospholipids and beeswax are fully mixed;

[0051] S7, controlling the temperature at 18° C. and the relative humidity at 45%, filling the mixture obtained in step S6 into capsule shells through a soft capsule machine, and pressing into soft capsules;

[0052] S8. Place the soft capsule in an environment with a temperature of 18° C. and a relative humidity of 35% for 2 hours to obtain the anti-oxidation soft capsule for protecting nerve cells.

[0053] Example 2

[0054] Each capsule content includes the following ingredients in parts by weight: 202 mg glycerylphosphorylcholine GPC, 255 mg algae oil DHA, 26 mg ergothioneine, 12 mg pyrroloquinoline quinone PQQ, 5.5 mg natural vitamin E, 75 mg medium chain triglyceride MCT, 31 mg non-transgenic phospholipids and 21 mg beeswax.

[0055] S1. Under vacuum conditions, preheat a mixture of gelatin, purified water and glycerin in a mass ratio of 100:100:35 to 79°C, pour it into a suction barrel and suck it into a steam-sterilized concentration pot through a pipeline. The steam sterilization temperature is 105°C and the time is 17 minutes.

[0056] S2. Continue to raise the temperature at a steam pressure of 0.08 MPa until the mixture is completely dissolved to obtain a mixed solution;

[0057] S3, continue heating to 103°C and perform vacuum degassing treatment on the mixed solution under a vacuum degree of -0.09MPa and a temperature of 60°C;

[0058] S4, filtering the mixed solution at a pressure of 0.05 MPa and a temperature of 60° C. to obtain a capsule solution;

[0059] S5, pouring the capsule shell solution into the molding container of the capsule molding machine, drying and shrinking for 19 hours at a temperature of 27° C. and a relative humidity of 35%, so that the moisture content of the soft capsule shell is reduced to 6%, and then washing with 95% ethanol to wash away the oil on the surface of the soft capsule shell;

[0060] S6. Under the condition of 24°C, glycerylphosphorylcholine GPC, DHA algae oil, ergothioneine, pyrroloquinoline quinone PQQ, natural vitamin E, medium chain triglyceride MCT, non-transformed phospholipids and beeswax are fully mixed;

[0061] S7, controlling the temperature at 22° C. and the relative humidity at 50%, and filling the mixture obtained in step S6 into capsule shells through a soft capsule machine, and pressing into soft capsules;

[0062] S8. Place the soft capsule in an environment with a temperature of 22° C. and a relative humidity of 35% for 3 hours to obtain the anti-oxidation soft capsule for protecting nerve cells.

[0063] Example 3

[0064] Each capsule content includes the following ingredients in parts by weight: 205 mg glycerylphosphorylcholine GPC, 250 mg algae oil DHA, 25 mg ergothioneine, 11 mg pyrroloquinoline quinone PQQ, 5 mg natural vitamin E, 74 mg medium chain triglyceride MCT, 30 mg non-transgenic phospholipids and 20 mg beeswax.

[0065] S1. Under vacuum conditions, preheat a mixture of gelatin, purified water and glycerin in a mass ratio of 100:100:35 to 82°C, pour it into a suction bucket and suck it into a steam-sterilized concentration pot through a pipeline, wherein the steam sterilization temperature is 110°C and the time is 20 minutes;

[0066] S2. Under a steam pressure of 0.1 MPa, continue to heat until the mixture is completely dissolved to obtain a mixed solution;

[0067] S3, continue heating to 105°C and perform vacuum degassing treatment on the mixed solution under a vacuum degree of -0.1MPa and a temperature of 60°C;

[0068] S4, filtering the mixed solution at a pressure of 0.06 MPa and a temperature of 62° C. to obtain a capsule solution;

[0069] S5, pouring the capsule shell solution into the molding container of the capsule molding machine, drying and shrinking for 24 hours at a temperature of 30° C. and a relative humidity of 35%, so that the moisture content of the soft capsule shell is reduced to 7%, and then washing with 95% ethanol to wash away the oil on the surface of the soft capsule shell;

[0070] S6. Under the condition of 24°C, glycerylphosphorylcholine GPC, DHA algae oil, ergothioneine, pyrroloquinoline quinone PQQ, natural vitamin E, medium chain triglyceride MCT, non-transformed phospholipids and beeswax are fully mixed;

[0071] S7, controlling the temperature at 26° C. and the relative humidity at 55%, filling the mixture obtained in step S6 into capsule shells through a soft capsule machine, and pressing into soft capsules;

[0072] S8. Place the soft capsule in an environment with a temperature of 26° C. and a relative humidity of 35% for 4 hours to obtain the anti-oxidation soft capsule for protecting nerve cells.

[0073] 1. Acute toxicity test:

[0074] The toxicological safety evaluation of health food was conducted in accordance with the "Procedures and Test Methods for Safety Toxicology Evaluation of Health Foods", and the test results are as follows:

[0075] The soft capsules prepared in Examples 1 to 3 were divided into three groups, with 20 SD rats (half male and half female) in each group. Each SD rat was fed at a dose of 20 g / kg, administered once, and observed for 14 consecutive days. No abnormalities were found in the general condition of the SD rats. The experimental results showed that the maximum tolerable dose of the soft capsule for SD rats was greater than 20 g / kg, and no toxic reactions occurred, which was non-toxic.

[0076] Comparative Example 1

[0077] The difference between Comparative Example 1 and Example 3 is that GPC is not added to the soft capsule content in Comparative Example 1, and the other operations are the same.

[0078] Comparative Example 2

[0079] The difference between Comparative Example 2 and Example 3 is that algae oil DHA is not added to the soft capsule content in Comparative Example 2, and the other operations are the same.

[0080] Comparative Example 3

[0081] The difference between Comparative Example 3 and Example 3 is that, in Comparative Example 3, ergothioneine is not added in the soft capsule content, and all the other operations are consistent.

[0082] Comparative Example 4

[0083] The difference between Comparative Example 4 and Example 3 is that PQQ is not added to the contents of the soft capsule in Comparative Example 4, and the other operations are the same.

[0084] Comparative Example 5

[0085] The difference between Comparative Example 5 and Example 3 is that, in Comparative Example 6, PQQ and thioneine are not added to the soft capsule content, and the other operations are all consistent.

[0086] Comparative Example 6

[0087] The difference between Comparative Example 6 and Example 3 is that PQQ and algae oil DHA are not added to the soft capsule content in Comparative Example 6, and the other operations are the same.

[0088] Comparative Example 7

[0089] The difference between Comparative Example 7 and Example 3 is that, in Comparative Example 7, ergothioneine and algae oil DHA are not added to the soft capsule content, and the other operations are all consistent.

[0090] Comparative Example 8

[0091] The difference between Comparative Example 8 and Example 3 is that, in Comparative Example 8, thioneine and GPC are not added in the soft capsule content, and the other operations are all consistent.

[0092] Comparative Example 9

[0093] The difference between Comparative Example 9 and Example 3 is that GPC and algae oil DHA are not added to the soft capsule content in Comparative Example 9, and the other operations are the same.

[0094] Comparative Example 10

[0095] The difference between Comparative Example 10 and Example 3 is that GPC and PQQ are not added to the soft capsule content in Comparative Example 10, and the other operations are the same.

[0096] Comparative Example 11

[0097] The difference between Comparative Example 11 and Example 3 is that ergothioneine, PQQ and algae oil DHA are not added to the soft capsule content in Comparative Example 11, and the other operations are consistent.

[0098] Comparative Example 12

[0099] The difference between Comparative Example 12 and Example 3 is that, in Comparative Example 12, GPC, ergothioneine and PQQ are not added to the soft capsule content, and the other operations are all consistent.

[0100] Comparative Example 13

[0101] The difference between Comparative Example 13 and Example 3 is that GPC, DHA and PQQ are not added to the content of the soft capsule in Comparative Example 13, and the other operations are the same.

[0102] Comparative Example 14

[0103] The difference between Comparative Example 14 and Example 3 is that, in Comparative Example 14, GPC, DHA and thioneine are not added in the soft capsule content, and the other operations are all consistent.

[0104] 2. Nerve protection test:

[0105] The efficacy of the soft capsules prepared in Examples 1-3 and Comparative Examples 1-9 on Alzheimer's disease model mice was studied:

[0106] AD model establishment: mice were injected with D-galactose solution at a dose of 120 mg / kg / d, and were gavaged with aluminum chloride solution at a dose of 10 mg / kg / d. The drug administration was continued for 60 days. The learning and memory abilities of mice were measured using a water maze, and AD mice were screened out. The normal group was injected with an equal amount of normal saline and gavaged with an equal amount of distilled water.

[0107] AD model mice were randomly divided into a blank group, a normal group, example groups 1-6 and comparative example groups 1-9 according to the random method in the animal grouping method, with 10 mice in each group and administered according to the following groups and dosages. The blank group and the normal group were gavaged with an equal amount of distilled water; the example groups 1-3 and the comparative example groups 1-9 were gavaged with the prepared soft capsules dissolved in warm water at 35-40°C, respectively, at a dosage of 0.5 g / kg / d, and the administration time was 30 days. At the same time as the administration, each group continued to be administered with the modeling agent to avoid natural recovery.

[0108] 1. Open box experiment

[0109] After grouping, the experimental mice were tested in an open box experiment. The experimental device of the open box experiment consists of two parts, an open box device and a recording device. The open box used is 30 cm high, 50 cm long and wide, empty inside, and the surrounding walls are painted black. The top of the open box is connected to a camera, and the camera is connected to a computer to record the experimental results. The bottom of the open box is divided into 25 blocks of equal area using computer software, with 16 blocks around the open box as the peripheral area and 9 blocks in the center as the central area. Each animal is measured once, and each time is 5 minutes. The open box memory experiment lasts for 5 days. On the 6th day of the experiment, the total distance of each mouse in the open box, as well as the time the mouse stays in the peripheral area and the central area, are recorded to calculate the proportion of peripheral time. After cleaning the open box each time, the next mouse is tested.

[0110] 2. Barnes maze test

[0111] After the open box test, the Barnes maze test was performed. The operation process of the Banes maze test was based on the Barnes method with some adjustments. The Barnes maze consists of a circular platform with 20 holes and a small, lightless recessed chamber called a "target box" at the bottom of one of the holes. The prototype platform has a diameter of 92 cm and the hole has a diameter of 5 cm. A camera was installed above the maze and connected to a computer. At the beginning of each training session, the mouse was placed in the center of the maze and was free to choose to enter the small hole on the platform. Each training session lasted for 4 minutes, and the time taken by the mouse to enter the target box within 4 minutes (escape latency) was recorded. If the mouse did not enter the target box within 4 minutes, the escape latency was recorded as 240 seconds. The test lasted for 6 days, with the first 5 days being the maze memory test period. The escape latency and number of errors were recorded on the 6th day. After each mouse was finished, the maze was wiped with alcohol, and the Barnes maze was rotated, but the relative spatial position of the target box was not changed to prevent the mouse from finding the location of the target box through information such as smell. The results are shown in Table 2.

[0112] Table 2

[0113]

[0114] As can be seen from Table 2, the total distance and peripheral proportion of Example Groups 1 to 3 are comparable to those of the normal group, and there is no significant difference in the physical fitness of mice in each group, and the peripheral time proportion is also comparable, indicating that there is no significant difference in the mental state of mice in Example Groups 1 to 3 and the normal group. The total distance and peripheral time proportion of Example Groups 1 to 3 are lower than those of the comparative group, indicating that the mental state of mice in the Example Group is better than that of the comparative group, indicating that the soft capsules of Example Groups 1 to 3 have higher body recovery ability for AD model mice than the soft capsules prepared in the comparative group. And the total distance and peripheral proportion of the Example Group and the Comparative Group are both less than the blank group, indicating that the mental state of mice in the blank group is inferior to that of mice in the Example Group and the Comparative Group, and the compositions of Example Groups 1 to 3 and Comparative Groups 1 to 14 have a promoting effect on the mental state, memory and body repair of AD model mice. The latency and number of errors of the mice in the embodiment group and the comparative group were lower than those in the blank group, indicating that the learning and memory abilities and cognitive functions of the mice in the embodiment group and the comparative group were far superior to those in the blank group, the cognitive functions of the mice in the blank group were severely impaired, and there was no significant difference between the data of the embodiment groups 1 to 3 and those of the normal group, that is, the learning and memory abilities and cognitive functions of the mice in the embodiment groups 1 to 3 were comparable to those of the mice in the normal group, indicating that the soft capsules in the embodiment group can effectively improve the cognitive disorders and behavioral disorders of the AD model mice and improve cognitive functions, proving that the invention can effectively protect nerves.

[0115] According to Example 3 and Comparative Example 2, GPC and DHA have a synergistic effect, and combined with Comparative Example 2 and Comparative Example 7, ergothioneine and PQQ have a synergistic effect; according to Example 3 and Comparative Example 3, GPC and ergothioneine have a synergistic effect, combined with Comparative Example 3 and Comparative Example 5, DHA and PQQ have a synergistic effect; according to Example 3 and Comparative Example 4, GPC and PQQ have a synergistic effect, combined with Comparative Example 4 and Comparative Example 6, DHA and ergothioneine have a synergistic effect, combined with Comparative Examples 1 to 14, when GPC, DHA, ergothioneine and PQQ are simultaneously present in the soft capsule, the cognitive ability of the mouse is optimal, and the effect is best at this time.

[0116] 3. Antioxidant function test:

[0117] (1) Modeling, drug administration, and experimental grouping

[0118] Modeling: 170 Wistar rats, weighing (126.21±2.61) g, half were female and half were male, and were randomly divided into 17 groups, with 10 rats in each group. Except for the blank group, the rats in the other groups were injected subcutaneously in the neck with 5% D-galactose 120 mg / kg every day to create an aging model.

[0119] Administration: Continuous intragastric administration was started on the 13th day of modeling for 30 days, and the administration volume for each group was 2 mL. After each administration, the rats were fasted but not watered for 24 hours, blood was collected from the fundus, and the blood was centrifuged after being allowed to stand at room temperature until it was completely coagulated. The rats were then killed by dislocation, and the brain tissue was quickly separated. After washing with sodium chloride solution, 10% tissue homogenate was prepared, centrifuged, and the tissue homogenate supernatant was separated for later use. The SOD activity and MDA content of brain tissue were determined by xanthine oxidase method and thiobarbituric acid spectrometry, respectively.

[0120] Trial Groups:

[0121] Example 3 of the present invention: The soft capsule of Example 3 was added with physiological saline to prepare a solution with a concentration of 0.5 g / mL;

[0122] Comparative groups 1-14: the soft capsules of comparative examples 1-14 were added with physiological saline to prepare a solution with a concentration of 0.5 g / mL;

[0123] Model group: normal saline;

[0124] Blank group: normal saline.

[0125] (2) Experimental results

[0126] Table 3

[0127]

[0128]

[0129] As shown in Table 3, there was no statistical difference in serum SOD activity and MDA content between the drug group of the present invention and the blank group, indicating that the soft capsule of the present invention can effectively enhance the body's ability to resist oxidation and scavenge free radicals, reduce the degree of tissue cell damage, and the indicators can basically be restored to the level before aging modeling.

[0130] Compared with the drug group of the present invention, the SOD activity of the comparative group was lower than that of the drug group of the present invention (P<0.05), and the MDA content was significantly higher (P<0.05), indicating that the anti-oxidation and anti-aging effects of the comparative group were not as good as those of the microcapsules prepared by the present invention, indicating that the combination of the present invention is the best, and reducing one of the components will reduce its anti-oxidation and anti-aging efficacy. The function of protecting nerves is achieved by protecting nerve cells from oxidative damage through its antioxidant activity and anti-apoptosis activity.

[0131] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technical personnel in this field can make some changes or modify the technical contents disclosed above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any brief modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are still within the scope of the technical solution of the present invention.

Claims

1. An anti-oxidation soft capsule for protecting nerve cells, characterized in that: The soft capsule comprises a soft capsule shell and capsule contents, wherein each portion of the capsule contents comprises the following components in parts by weight: 200-205 portions of glycerylphosphorylcholine GPC, 250-260 portions of algae oil DHA, 25-27 portions of ergothioneine, 10-12 portions of pyrroloquinoline quinone PQQ, 5-6 portions of natural vitamin E, 73-75 portions of medium-chain triglycerides MCT, 30-33 portions of non-transgenic phospholipids and 20-22 portions of beeswax; and the soft capsule shell is prepared by gelatin, purified water and glycerol.

2. The preparation process of the anti-oxidation and nerve cell protection soft capsule according to claim 1, characterized in that: The following steps are involved: S1. Preheat the mixture of gelatin, purified water and glycerin to 78-82°C under vacuum conditions, pour it into a suction bucket and suck it into a steam-sterilized concentrator through a pipeline; S2. Continue to raise the temperature at a steam pressure of 0.06-0.1 MPa until the mixture is completely dissolved to obtain a mixed solution; S3, continue heating to 100-105°C to perform vacuum degassing on the mixed solution; S4, filtering the mixed solution at a pressure of 0.03-0.06 MPa and a temperature of 58-62° C. to obtain a capsule solution; S5, pouring the capsule shell solution into a molding container of a capsule molding machine, drying and shrinking the soft capsule shell to reduce the moisture content of the soft capsule shell to 5-7%, and then washing with 95% ethanol to remove the oil stain on the surface of the soft capsule shell; S6. At 24° C., mix glycerylphosphorylcholine GPC, algae oil DHA, ergothioneine, pyrroloquinoline quinone PQQ, natural vitamin E, medium-chain triglyceride MCT, non-transformed phospholipids and beeswax in proportions by weight. S7, controlling the temperature at 18-26° C. and the relative humidity at 45-55%, filling the mixture obtained in step S6 into capsule shells through a soft capsule machine, and pressing into soft capsules; S8, placing the soft capsule in an environment with a temperature of 18-26° C. and a relative humidity of 35% for 2-4 hours to obtain the anti-oxidation soft capsule for protecting nerve cells.

3. The preparation process of the anti-oxidation and nerve cell protection soft capsule according to claim 2, characterized in that: In step S1, the mass ratio of gelatin, purified water and glycerol is 100:100:

35.

4. The preparation process of the anti-oxidation and nerve cell protection soft capsule according to claim 2, characterized in that: In step S1, the steam sterilization temperature is 100-110°C and the time is 15-20 minutes.

5. The preparation process of the anti-oxidation and nerve cell protection soft capsule according to claim 2, characterized in that: In step S3, the vacuum degree during vacuum degassing is -0.08 to -0.1 MPa and the temperature is 60°C.

6. The preparation process of the anti-oxidation and nerve cell protection soft capsule according to claim 2, characterized in that: In step S5, the drying shrinkage conditions are a temperature of 25 to 30° C., a relative humidity of 35%, and a time of 18 to 24 hours.

Citation Information

Patent Citations

  • Soft capsule for improving cranial nerve function and preparation method thereof

    CN102552212A

  • Health-care formula containing SOD (superoxide dismutase) and ergothioneine and having functions of resisting fatigue, resisting oxidation and dispelling effects of alcohol

    CN114271490A

  • DHA algal oil zinc taurine soft capsule and preparation method thereof

    CN115553467A

Cited By

  • Micro-crystallized glycerophosphorylcholine-polysaccharide compound as well as preparation method and application thereof

    CN120092955A

  • Anti-aging composition

    CN121489969A